Ligand Pharmaceuticals Incorporated Contingent Value Rights (LGNYZ)

Overview

Ligand Pharmaceuticals Incorporated stands out as a pioneering biopharmaceutical entity, deeply engaged in the growth and licensing of biopharmaceutical products across the globe. This company, established in 1987 and headquartered in Jupiter, Florida, has carved a niche for itself through strategic partnerships, licenses, and business engagements with leading pharmaceutical corporations including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Beyond its focus on licensing innovative drug technologies, Ligand Pharmaceuticals also specializes in the sale of Captisol materials, enhancing the bioavailability of drugs.

Products and Services

Ligand Pharmaceuticals' vast and varied product portfolio serves multiple therapeutic areas, showcasing a strong commitment to addressing rare and common diseases alike.

• Kyprolis and Evomela - Both are actively utilized in the treatment of multiple myeloma, demonstrating Ligand's focus on cancer therapeutics.
• Rylaze - This recombinant erwinia asparaginase is used in managing acute lymphoblastic leukemia or lymphoblastic lymphoma in both adult and pediatric patients, contributing to Ligand's efforts in leukemia treatment.
• Filspari - Currently in development, this treatment represents a novel approach targeting rare kidney diseases with its dual endothelin and angiotensin II receptor antagonism, aimed specifically at immunoglobulin A nephropathy.
• Teriparatide Injection - This product caters to patients with osteoporosis, offering them a therapeutic option to manage their condition.
• Vaxneuvance - A preventative measure against invasive diseases caused by Streptococcus pneumoniae serotypes, advocating for Ligand's investment in vaccine development.
• Pneumosil - This pneumococcal conjugate vaccine plays a crucial role in combatting pneumococcal pneumonia among children, underlining the company's commitment to child health.
• TZIELD - A CD3-directed antibody for delaying the progression to Stage 3 type 1 diabetes in patients aged 8 and older with Stage 2 T1D, marking a significant advancement in diabetes care.
• Nexterone - This captisol-enabled formulation of amiodarone underscores Ligand's expertise in enhancing drug delivery and solubility.
• Zulresso - A captisol-enabled formulation of brexanolone aimed at treating postpartum depression, highlighting the company's focus on mental health.
• Veklury - Demonstrates Ligand's responsiveness to pandemic challenges with this antiviral treatment for moderate or severe COVID-19.
• Noxafil-IV - This captisol-enabled formulation of posaconazole for IV use represents an innovative solution to fungal infections.
• Duavee - Addresses post-menopausal symptoms in women, showcasing Ligand's commitment to women's health.
• Exemptia, Vivitra, Bryxta, and Zybev - These products serve various indications, including but not limited to autoimmune diseases and breast cancer, further expanding Ligand's therapeutic reach.